IGC Pharma (IGC) Operating Income (2010 - 2025)
IGC Pharma (IGC) posted quarterly Operating Income of -$2.9 million for Q3 2025, down 64.72% year-over-year from -$8.2 million in Q3 2024, and down 52.18% quarter-over-quarter from -$1.9 million in Q2 2025.
IGC Pharma (IGC) Operating Income (2010 - 2025) Analysis & Trends
IGC Pharma (IGC) has reported Operating Income for 16 consecutive years, with -$2.9 million the latest figure, recorded in Q3 2025.
- In Q3 2025, Operating Income fell 64.72% year-over-year to -$2.9 million; the TTM figure through Sep 2025 stood at -$8.1 million (up 13.18% YoY), while the FY2026 annual figure was -$2.5 million, up 66.99% from the prior year.
- Operating Income declined to -$2.9 million in Q3 2025 per IGC's latest filing, from -$1.9 million in the prior quarter.
- Across five years, Operating Income topped out at -$1.4 million in Q1 2025 and bottomed at -$6.5 million in Q1 2022.
- Historically, Operating Income has averaged -$2.7 million across 5 years, with a median of -$2.4 million in 2024.
- Annual changes were most pronounced in 2021 — Operating Income plunged 159.43% — and 2024, when it surged 46.27%.
- IGC Pharma's Operating Income stood at -$2.4 million in 2021, then gained by 4.49% to -$2.3 million in 2022, then tumbled by 31.61% to -$3.0 million in 2023, then soared by 37.36% to -$1.9 million in 2024, then plunged by 54.37% to -$2.9 million in 2025.
- Business Quant data shows IGC's Operating Income at -$2.9 million in Q3 2025, -$1.9 million in Q2 2025, and -$1.4 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | IGC Pharma | 27.20 Mn | 26.94 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -2.90 Mn |
| Jun 30, 2025 | -1.91 Mn |
| Mar 31, 2025 | -1.41 Mn |
| Dec 31, 2024 | -1.88 Mn |
| Sep 30, 2024 | -1.76 Mn |
| Jun 30, 2024 | -2.40 Mn |
| Mar 31, 2024 | -2.17 Mn |
| Dec 31, 2023 | -3.00 Mn |
| Sep 30, 2023 | -2.49 Mn |
| Jun 30, 2023 | -2.14 Mn |
| Mar 31, 2023 | -4.04 Mn |
| Dec 31, 2022 | -2.28 Mn |
| Sep 30, 2022 | -2.49 Mn |
| Jun 30, 2022 | -2.80 Mn |
| Mar 31, 2022 | -6.50 Mn |
| Dec 31, 2021 | -2.39 Mn |
| Sep 30, 2021 | -4.35 Mn |
| Jun 30, 2021 | -2.19 Mn |
| Mar 31, 2021 | -2.79 Mn |
| Dec 31, 2020 | -2.33 Mn |